Загрузка...
Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease
Alzheimer’s disease (AD) affects more than twenty-five million people worldwide and is the most common form of dementia. Symptomatic treatments have been developed, but effective intervention to alter disease progression is needed. Targets have been identified for disease-modifying drugs, but the re...
Сохранить в:
| Опубликовано в: : | J Neural Transm |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4305447/ https://ncbi.nlm.nih.gov/pubmed/22354745 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00702-012-0772-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|